ClinicalTrials.gg
RecruitingNCT07195149OPTIMUS-CABGUpdated Oct 27, 2026

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

A Phase 3 interventional study of High-Dose Aspirin 300 mg and DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg) in Chronic Coronary Syndrome and Stable Coronary Artery Disease CAD, sponsored by Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.. Recruiting at 18 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 27, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,703
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing aspirin in Coronary Artery Disease — 8 open to participants now, 9 under way, 1 of them phase 3. Aspirin · Coronary Artery Disease.

Planned enrollment
17th of 53
1,703 · median 200
Started
2025
the only one that year
Phase 3
7 of 53
1 open now
Registered
51st of 53
by date

Among the 53 studies testing aspirin in Coronary Artery Disease, this one is the 17th largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 3, and was the 51st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 53 studies testing aspirin in Coronary Artery Disease are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aspirin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.

Read the detailed description

This is a multicenter, randomized trial evaluating the effect of low-dose aspirin plus prasugrel versus low-dose ASA and versus high-dose ASA for three months, followed by low-dose ASA alone, on graft failure at 12 months in patients with stable coronary artery disease (chronic coronary syndrome) following a coronary artery bypass grafting.

03

Conditions studied

  • Chronic Coronary Syndrome
  • Stable Coronary Artery Disease CAD

Keywords

  • DAPT
  • CABG
  • Prasugrel
  • Aspirin
  • CCS
  • Chronic coronary syndrome
  • Stable coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Baseline (preoperative) inclusion criteria

  1. Age >18 years
  2. Primary isolated CABG patients with stable coronary artery disease (chronic coronary syndrome) planned for at least 2 grafts. Coronary artery disease will be defined as a stenosis ≥ 70% based on coronary angiography, a FFR value ≤ 0.80 or iFr value ≤0.89; a left main diameter stenosis ≥ 50%, left main IVUS MLA value ≤ 6 mm2, or equivalent OCT measurements will also be considered.
  3. Ability to comply with all study procedures and follow-up procedures
  4. Signed to participate in the study.

B. Operative inclusion criteria:

  1. Intraoperative graft evaluation using transit time flow measurement in all grafts, normal flow in any graft is defined as mean graft flow > 15 mL/min with Pulsatility Index \< 5
  2. Left anterior descending artery grafted with internal thoracic artery
  3. No intraoperative decision for hybrid revascularization due to incomplete revascularization (Percutaneous coronary intervention (PCI) of the ungrafted vessel)
  4. No endarterectomy of the grafted vessel performed
  5. Patient did not have any additional unplanned procedure (Ex. LAAC, Ablation, valve intervention, aortic intervention)

Exclusion criteria

Exclusion Criteria:

A. Baseline (preoperative) exclusion criteria:

  1. Cardiogenic shock
  2. Patients with recent acute coronary syndrome (ACS) (\<12 months)
  3. Single vessel CABG
  4. Patients with preoperative atrial fibrillation
  5. Dialysis
  6. Thrombocytopenia ( count \< 100 000 platelets/uL)
  7. Anemia ( level \< 10 g/dL)
  8. Severe liver failure classification >4
  9. Known, active infections with , , , tuberculosis
  10. Active malignant disease or history of within the past 5 years
  11. Indication for DAPT (e.g. recent PCI or ACS or recent stents of peripheral arteries)
  12. Indication for oral anticoagulant treatment 13 Indications for the use of methotrexate at a dose of 15 mg/week or more

14. Any for prasugrel or ASA 15. Planned additional cardiac or non-cardiac surgery within 12 months 16. Non-cardiac co-morbidity with less than 12 months 17. History of any bleeding complications due to the use of DAPT 18. History of intracranial bleeding 19. History of gastro-intestinal bleeding 20. Pregnancy or breastfeeding 21. Lack of compliance with the use of a highly effective method of 22. Planned coronary endarterectomy 23. Severe impaired renal function ( \<40mL/min/1.73 m2).

B. Postoperative and prior randomization exclusion criteria:

  1. Perioperative cardiogenic shock
  2. Intraoperative death or death prior randomization
  3. Myocardial infarction within 12-24 hours following CABG or prior randomization
  4. Ischemic or hemorrhagic stroke within 12-24 hours following CABG or prior randomization
  5. Any postoperative complication that may increase patients' risk with DAPT
  6. Atrial Fibrillation prior randomization
  7. Gastro-intestinal bleeding prior randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,703 participants (estimated)

Study arms

  • Experimental
    Prasugrel 10 mg + Low Dose Aspirin 75 mg

    Drug: DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)

  • Active comparator
    Low-Dose Aspirin 75 mg

    Drug: Low-Dose Aspirin 75 mg

  • Active comparator
    High-Dose Aspirin 300 mg

    Drug: High-Dose Aspirin 300 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of graft failure: DAPT vs Low-Dose Aspirin and DAPT vs High-Dose Aspirin

    Incidence of graft failure defined according to Fitzgibbon classification (Fitzgibbon Class B + O) 12 months after the randomization following CABG in patients with DAPT (prasugrel 10mg/day + low dose aspirin 75mg/day) versus high-dose aspirin (300mg/day) and in patients with DAPT (prasugrel 10mg/day + low dose aspirin 75mg/day) vs low-dose aspirin (75mg/day)

    Time frame: 12 months

Secondary outcomes

  1. Key secondary outcome: Incidence of graft failure: High-Dose Aspirin vs Low-Dose Aspirin

    Incidence of graft failure defined according to Fitzgibbon classification (Fitzgibbon Class B + O) 12 months after the randomization following CABG in patients with high-dose aspirin (300mg/day) vs low-dose aspirin (75mg/day)

    Time frame: 12 months

  2. investigatigating the effect of DAPT versus low-dose aspirin, DAPT versus high-dose aspirin and low-dose aspirin versus high-dose aspirin on the 12-month risk of ischemic events after CABG

    Major adverse cardiac and cerebral events (MACCE) is a composite endpoint to be compared between groups defined as composite of: 1. All-cause mortality 2. Incidence of myocardial infarction 3. Incidence of stroke 4. Incidence of repeat revascularization

    Time frame: 12 months

  3. Investigatigating the effect of DAPT versus low-dose aspirin, DAPT versus high-dose aspirin and low-dose aspirin versus high-dose aspirin on the 12-month risk of bleeding events after CABG

    Incidence of bleeding within 12 months after randomization following CABG procedure according to the Bleeding Academic Research Consortium (BARC) type 2, 3 or 5

    Time frame: 12 months

  4. Investigatigating the effect of DAPT versus low-dose aspirin, DAPT versus high-dose aspirin and low-dose aspirin versus high-dose aspirin on quality of life at 6 and 12 months after CABG.

    Quality of life will be assessed using quality of life questionnaires at baseline, 6 and 12 months after randomization following CABG procedure and will be evaluated using The Seattle Angina Questionnaire - 7 (SAQ-7) and Short-form-12 health survey questionnaire (SF-12)

    Time frame: 12 months

  5. investigatigating the effect of DAPT versus low-dose aspirin, DAPT versus high-dose aspirin and low-dose aspirin versus high-dose aspirin on the 60-month risk of ischemic events after CABG

    Major adverse cardiac and cerebral events (MACCE) is a composite endpoint to be compared between groups defined as composite of: 1. All-cause mortality 2. Incidence of myocardial infarction 3. Incidence of stroke 4. Incidence of repeat revascularization

    Time frame: 60 months

07

Study locations

8 of 18 sites recruiting
  • University Clinical Hospital in Bialystok
    Bialystok, Poland
    Active, not recruiting

    Not enrolling at this site.

  • Nicolaus Copernicus University Ludwik Rydygier Collegium Medicum in Bydgoszcz
    Bydgoszcz, Poland
    Not yet recruiting
    • Wojciech Pawliszak, MD, PhD · Contact
  • Medical University of Gdansk
    Gdansk, Poland
    Not yet recruiting
    • Andrzej Los, MD, PhD · Contact
  • Regional Specialist Hospital in Grudziadz
    Grudziądz, Poland
    Not yet recruiting
    • Marian Burysz, MD, PhD · Contact
  • Upper-Silesian Heart Center
    Katowice, Poland
    Recruiting
    • Radoslaw Gocol, MD, PhD · Contact
  • John Paul II Hospital
    Krakow, Poland
    Not yet recruiting
    • Janusz Konstanty-Kalandyk, MD, PhD · Contact
  • Medical University of Lodz
    Lodz, Poland
    Not yet recruiting
    • Michal Krejca, MD, PhD · Contact
  • Zbigniew Religa Heart Center "Medinet"
    Nowa Sól, Poland
    Recruiting
    • Sleiman Sebastian Aboul-Hassan, MD, PhD · Contact
  • Provincial Specialist Hospital in Olsztyn
    Olsztyn, Poland
    Not yet recruiting
    • Anna Witt-Majchrzak, MD, PhD · Contact
  • Institute of Medical Sciences in Opole
    Opole, Poland
    Recruiting
    • Marek Cisowski, MD, PhD · Contact
  • J. Struś Hospital
    Poznan, Poland
    Not yet recruiting
    • Pawel Bugajski, MD, PhD · Contact
  • Poznan University of Medical Sciences
    Poznan, Poland
    Active, not recruiting

    Not enrolling at this site.

  • Pomeranian Medical University
    Szczecin, Poland
    Not yet recruiting
    • Jerzy Pacholewicz, MD, PhD · Contact
  • Central Clinical Hospital of the Ministry of Interior and Administration
    Warsaw, Poland
    Recruiting
    • Mariusz Kowalewski, MD, PhD · Contact
  • Medicover Hospital
    Warsaw, Poland
    Recruiting
    • Krzysztof Wrobel, MD, PhD · Contact
  • Wroclaw Medical University
    Wroclaw, Poland
    Recruiting
    • Maciej Bochenek, MD · Contact
  • Zbigniew Religa Heart Center "Medinet"
    Wroclaw, Poland
    Recruiting
    • Mikolaj Berezowski, MD · Contact
  • Silesian Centre for Heart Diseases in Zabrze
    Zabrze, Poland
    Recruiting
    • Tomasz Hrapkowicz, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2030, 53 months after the start.

Of 62 phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 26, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Apr 30, 2030
CompletionEst.
Nov 30, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (4 now recruiting, 1 now active, not recruiting)
Show 5 sites
  • University Clinical Hospital in Bialystok · Bialystok, PolandNot yet recruiting→Active, not recruiting
  • Upper-Silesian Heart Center · Katowice, PolandActive, not recruiting→Recruiting
  • Institute of Medical Sciences in Opole · Opole, PolandNot yet recruiting→Recruiting
  • Central Clinical Hospital of the Ministry of Interior and Administration · Warsaw, PolandActive, not recruiting→Recruiting
  • Wroclaw Medical University · Wroclaw, PolandActive, not recruiting→Recruiting
Oct 27, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • University Clinical Hospital in Bialystok · Bialystok, PolandContact removed (no phone or email listed)
  • Upper-Silesian Heart Center · Katowice, PolandContact added (no phone or email listed)
  • Central Clinical Hospital of the Ministry of Interior and Administration · Warsaw, PolandContact added (no phone or email listed)
  • Wroclaw Medical University · Wroclaw, PolandContact added (no phone or email listed)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    5 sites changed recruiting status (4 now recruiting, 1 now active, not recruiting)
    Show 5 sites
    • University Clinical Hospital in Bialystok · Bialystok, PolandNot yet recruiting→Active, not recruiting
    • Upper-Silesian Heart Center · Katowice, PolandActive, not recruiting→Recruiting
    • Institute of Medical Sciences in Opole · Opole, PolandNot yet recruiting→Recruiting
    • Central Clinical Hospital of the Ministry of Interior and Administration · Warsaw, PolandActive, not recruiting→Recruiting
    • Wroclaw Medical University · Wroclaw, PolandActive, not recruiting→Recruiting
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • University Clinical Hospital in Bialystok · Bialystok, PolandContact removed (no phone or email listed)
    • Upper-Silesian Heart Center · Katowice, PolandContact added (no phone or email listed)
    • Central Clinical Hospital of the Ministry of Interior and Administration · Warsaw, PolandContact added (no phone or email listed)
    • Wroclaw Medical University · Wroclaw, PolandContact added (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07195149
Lead sponsor
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Collaborators
Medical Research Agency, Poland
Responsible party
Sleiman Sebastian Aboul-Hassan (Principal Investigator: Sleiman Sebastian Aboul-Hassan MD, PhD, Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.) — Principal investigator
First posted
Sep 26, 2025
Start date
Nov 25, 2025
Primary completion
Apr 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Aleksandra Pawlik
Contact
badaniakliniczne@medinet.pl
+48 71 320 94 50
Sleiman Sebastian Aboul-Hassan, MD, PhD
principal investigator · Zbigniew Religa Heart Center "Medinet"

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Diaminohydroxypropanetetraacetic acid

Start the discussion